beta

ADMP

Adamis Pharmaceuticals Corp

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

Market Cap: 7.19 Million

Primary Exchange: NASDAQ

Website: http://www.adamispharmaceuticals.com/

Shares Outstanding: 9.36 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.0

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2863 trading days

From: 2013-02-12 To: 2023-05-19

Lowest Point:

Adamis: Share Price Continues To Grind Down To A Fine Discount

via: SeekingAlpha at 2019-06-13 04:24:20:000

Adamis Pharmaceuticals ( ADMP ) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval fo… read more...

Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval

via: SeekingAlpha at 2019-06-11 07:39:43:000

Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...

Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval

via: SeekingAlpha at 2019-06-11 07:39:43:000

Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2013-12-13 17.0 1.0 17.0
Data provided by IEX Cloud